News | December 17, 2025
Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Angelini Ventures has already invested €125 million in 22 startups
Subscribe To Our Newsletter & Stay Updated
